Home›Clinical trials›California

GLP-1 clinical trials in California: 51 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

51 GLP-1 clinical trials are recruiting at 192 sites in 72 cities across California. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in California

  1. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06857942.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    10 sites in California
    • Medvin Clinical Research - Apple Valley, Apple Valley. 909-581-8477
    • Medvin Clinical Research - Covina, Covina. 626-869-5730
    • Newport Huntington Medical Group, Huntington Beach. 714-378-2440
    • Purushotham & Akther Kotha MD, Inc, La Mesa. 619-229-1995 x208
    • Medvin Clinical Research - Riverside, Riverside. (951) 672-1866
    • Rheumatology Center of San Diego, San Diego
    • Providence Saint John's Medical Foundation, Santa Monica
    • Medvin Clinical Research - Temecula, Temecula. 9516525000
    • Medvin Clinical Research - Tujunga, Tujunga. 8182652250
    • Medvin Clinical Research - Whittier, Whittier. 5627586600

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06864026.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    4 sites in California

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

    Phase 4. Stanford University plans to enroll 104 participants.

    Who can join. Adults 30 to 70, have type 2 diabetes, BMI 19+.

    2 sites in California

    • Stanford University, Palo Alto. 408-896-0134
    • Stanford University, Clinical and Translational Research Unit (CTRU), Stanford. 408-896-0134

    NCT06657209 on ClinicalTrials.gov. See whether you qualify.

  1. A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in California

    • Eastside Clinical Research Associates, Los Angeles. 323-261-4706

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Phase 4. Matthew J. Budoff plans to enroll 120 participants.

    Who can join. Adults 40 to 80, have type 2 diabetes, BMI 25+.

    1 site in California

    • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance. 310-222-4107

    NCT05708859 on ClinicalTrials.gov. See whether you qualify.

  3. A study listed on ClinicalTrials.gov.

    Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

    Phase 4. Kalpna Kay Durairaj, MD, FACS plans to enroll 48 participants.

    1 site in California

    • K. Kay Durairaj, MD, A Medical Corp., Pasadena. 8183167033

    NCT07419854 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    25 sites in California

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    16 sites in California

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    14 sites in California

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    12 sites in California

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

The other 41 studies recruiting in California

  1. A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    11 sites in California
    • Headlands Research California, LLC, Escondido
    • Neighborhood Healthcare, Escondido
    • Diabetes & Endocrine Specialists - La Mesa, La Mesa
    • Clinical Trials Research_Sacramento, Lincoln
    • Loma Linda University Faculty Medical Clinics, Loma Linda
    • Pacific Clinical Studies, Los Alamitos
    • Valley Clinical Trials, Northridge
    • Desert Oasis Healthcare, Palm Springs
    • Linda Vista Health Care Ctr, San Diego
    • Velocity Clin Res - Van Nuys, Van Nuys
    • Flourish Research - CA, Walnut Creek

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    7 sites in California
    • Research Site, Covina
    • Research Site, Encinitas
    • Research Site, Garden Grove
    • Research Site, Loma Linda
    • Research Site, Long Beach
    • Research Site, Pomona
    • Research Site, Sacramento

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    Who can join. Children and teens 6 to 17, have obesity.

    5 sites in California
    • Loma Linda University School of Medicine, Loma Linda
    • Childrens Hospital of Los Angeles, Los Angeles
    • UCLA Mattel Children's Hospital, Los Angeles
    • Children's Hospital of Orange County - Orange, Orange
    • Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Oxnard. 805-483-1185 x.947

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    5 sites in California

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    5 sites in California
    • Desert Oasis Healthcare Medical Group, Palm Springs
    • Inland Empire Liver Foundation, Rialto
    • Peninsula Research Associates, Rolling Hills Estates
    • Apex Clinical Research, San Diego
    • Southern California Clinical Research, Santa Ana

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    4 sites in California

    • Smart Cures Clinical Research, Anaheim
    • Cedars-Sinai Medical Center, Beverly Hills. 310-423-4100
    • United Medical Doctors - Los Alamitos, Los Alamitos. 562-430-4449
    • California Medical Research Associates, Northridge. 818-349-1979

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    4 sites in California

    • Smart Cures Clinical Research, Anaheim
    • Cedars-Sinai Medical Center, Beverly Hills. 310-423-4100
    • United Medical Doctors - Los Alamitos, Los Alamitos. 562-430-4449
    • California Medical Research Associates, Northridge. 818-349-1979

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  8. A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Altimmune, Inc plans to enroll 1,800 participants.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    4 sites in California

    • Altimmune Clinical Study Site, Fountain Valley
    • Altimmune Clinical Study Site, Fresno
    • Altimmune Clinical Study Site, Gardena
    • Altimmune Clinical Study Site, Long Beach

    NCT07795164 on ClinicalTrials.gov. See whether you qualify.

  9. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    3 sites in California

    • Matrix Clinical Research, Los Angeles. 310-424-5922
    • Alarcon Urology Center, Montebello
    • Prestige Medical Group, Tustin

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  10. A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    3 sites in California

    • VA Long Beach Healthcare System, Long Beach, CA, Long Beach. 562-826-8000
    • VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto. 650-493-5000
    • VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles. 310-268-3528

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  11. A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Vanda Pharmaceuticals plans to enroll 280 participants.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    3 sites in California

    NCT07446439 on ClinicalTrials.gov. See whether you qualify.

  12. A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 450 participants.

    Who can join. Adults 18+, are overweight, BMI 27+.

    3 sites in California

    • Headlands Research California, LLC, Escondido
    • National Research Institute - Huntington Park, Huntington Park
    • Los Angeles Institute for Metabolic Research, Los Angeles

    NCT07770841 on ClinicalTrials.gov. See whether you qualify.

  13. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Eli Lilly and Company plans to enroll 300 participants.

    Who can join. Children and teens 12 to 17, have obesity.

    2 sites in California

    • Children's Hospital Los Angeles, Los Angeles
    • Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento

    NCT06439277 on ClinicalTrials.gov. See whether you qualify.

  14. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in California

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  15. A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in California

    • Kailera Clinical Site, Northridge
    • Kailera Clinical Site, Oceanside

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  16. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in California

    • Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Oxnard

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  17. A study testing whether a GLP-1 medicine, semaglutide, can help people with obesity lose weight.

    Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

    Phase 3. Children's Hospital Los Angeles plans to enroll 150 participants.

    Who can join. Children and teens 12 to 18, have obesity, BMI 35+.

    1 site in California

    • Children's Hospital Los Angeles, Los Angeles

    NCT06934655 on ClinicalTrials.gov. See whether you qualify.

  18. A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in California

    • Neighborhood Healthcare, Escondido

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  19. A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    6 sites in California
    • First Valley Medical Group, Lancaster
    • Torrance Clinical Research Institute, Inc., Lomita
    • Ark Clinical Research, Long Beach
    • Pacific Clinical Studies, Los Alamitos
    • Wetlin Research Associates, Inc., San Diego
    • Diablo Clinical Research, Inc., Walnut Creek

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  20. A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in California

    • NorCal Medical Research, Inc, Greenbrae. 415-461-1585
    • Velocity Clinical Research, Huntington Park, Huntington Park. 323-588-1990
    • Peninsula Research Associates, Rolling Hills Estates. 310-265-1623
    • Diablo Clinical Research, Inc., Walnut Creek. 925-930-7267

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  21. A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    4 sites in California

    • Hope Clinical Research, Canoga Park
    • Ark Clinical Research, Long Beach
    • Catalina Research Institute, LLC, Montclair
    • Paradigm Clinical Research Centers, LLC, San Diego

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

  22. A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    4 sites in California

    • Ark Clinical Research, Fountain Valley
    • Ark Clinical Research, Long Beach
    • Los Angeles Institute for Metabolic Research, Los Angeles
    • Catalina Research Institute, LLC, Montclair

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  23. A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    2 sites in California

    • N America Res Inst - San Dimas, San Dimas
    • NorCal Endocrinology and Internal Medicine, San Ramon

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  24. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    Phase 2. Regeneron Pharmaceuticals plans to enroll 204 participants.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD), BMI 30+.

    2 sites in California

    • Southern California Research Center, Coronado
    • California Liver Research Institute, Pasadena

    NCT07527910 on ClinicalTrials.gov. See whether you qualify.

  25. A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in California

    • FDRC, Costa Mesa
    • Los Angeles Institute for Metabolic Research, Los Angeles

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  26. A study testing whether a GLP-1 medicine, semaglutide, can help people with chronic kidney disease protect their kidneys.

    Sit Less, Interact and Move More (SLIMM) 2 Study

    Phase 2. Srinvasan Beddhu plans to enroll 156 participants.

    Who can join. Adults 20+, have chronic kidney disease.

    1 site in California

    NCT05173714 on ClinicalTrials.gov. See whether you qualify.

  27. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

    Phase 2. Stanford University plans to enroll 66 participants.

    Who can join. Adults 18 to 70, have obesity, BMI 27+.

    1 site in California

    • Clinical and Translational Research Unit, Palo Alto. 650-888-0144

    NCT05912621 on ClinicalTrials.gov. See whether you qualify.

  28. A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in California

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  29. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

    Phase 2. Washington University School of Medicine plans to enroll 60 participants.

    Who can join. Adults 18 to 80, have Crohn's disease, BMI 25+.

    1 site in California

    NCT06976853 on ClinicalTrials.gov. See whether you qualify.

  30. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with alcohol use disorder drink less.

    Tirzepatide for Alcohol Use Disorder

    Phase 2. University of Southern California plans to enroll 42 participants.

    Who can join. Adults 21 to 65, have alcohol use disorder, BMI 27+.

    1 site in California

    • Keck School of Medicine, University of Southern California, Los Angeles. 2139620698

    NCT06994338 on ClinicalTrials.gov. See whether you qualify.

  31. A study of a GLP-1 and GIP medicine, tirzepatide, in people with prostate cancer.

    A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen

    Phase 2. City of Hope Medical Center plans to enroll 60 participants.

    Who can join. Adults 30 to 79, have prostate cancer, BMI 27+.

    1 site in California

    NCT07202247 on ClinicalTrials.gov. See whether you qualify.

  32. A study of a GLP-1 medicine, semaglutide, in people with methamphetamine dependence.

    Glutide for Ending Methamphetamine

    Phase 2. San Francisco Department of Public Health plans to enroll 162 participants.

    Who can join. Adults 18 to 65, have methamphetamine dependence, BMI 25+.

    1 site in California

    • Center on Substance Use and Health, San Francisco. 6282176235

    NCT07204249 on ClinicalTrials.gov. See whether you qualify.

  33. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. University of Southern California plans to enroll 300 participants.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in California

    • Keck School of Medicine, University of Southern California, Los Angeles. 213-962-0698

    NCT07602699 on ClinicalTrials.gov. See whether you qualify.

  34. A study testing whether a GLP-1 and GIP medicine from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

    Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

    Phase 2. Regeneron Pharmaceuticals plans to enroll 360 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in California

    • Diablo Clinical Research - Flourish Research, Walnut Creek

    NCT07685808 on ClinicalTrials.gov. See whether you qualify.

  35. A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Antag Therapeutics plans to enroll 150 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    1 site in California

    NCT07724340 on ClinicalTrials.gov. See whether you qualify.

  36. A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents

    Phase 1. Novo Nordisk A/S plans to enroll 71 participants.

    Who can join. Adults 18+, have obesity, BMI 25+.

    1 site in California

    • Altasciences Clinical LA, Inc., Cypress

    NCT07225816 on ClinicalTrials.gov. See whether you qualify.

  37. A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Novo Nordisk A/S plans to enroll 114 participants.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in California

    • Diablo Clinical Research, Inc., Walnut Creek

    NCT07607587 on ClinicalTrials.gov. See whether you qualify.

  38. A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects

    University of California, Los Angeles plans to enroll 20 participants.

    Who can join. Adults 18+, have obesity.

    1 site in California

    • UCLA Health, Los Angeles

    NCT05419726 on ClinicalTrials.gov. See whether you qualify.

  39. A study in people with coronary artery stenosis.

    Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous

    Duk-Woo Park, MD plans to enroll 1,500 participants.

    Who can join. Adults 20+, have coronary artery stenosis.

    1 site in California

    • Palo Alto VA Medical Center, Palo Alto

    NCT05831085 on ClinicalTrials.gov. See whether you qualify.

  40. A study listed on ClinicalTrials.gov.

    Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor

    Cytrellis Biosystems, Inc plans to enroll 10 participants.

    1 site in California

    NCT07224880 on ClinicalTrials.gov. See whether you qualify.

  41. A study listed on ClinicalTrials.gov.

    A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health

    Athletic Greens International plans to enroll 120 participants.

    Who can join. Adults 18 to 59, BMI 20+.

    1 site in California

    NCT07437911 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.